ANDA 208474, held by B Braun Medical. Lidocaine Hydrochloride.
As of Nov 16, 2026, ANDA 208474 (Lidocaine Hydrochloride), held by B Braun Medical, was first approved by FDA on Aug 3, 2018, with 1 approved supplement and 0 published complete response letters.
INDICATIONS AND USAGE Lidocaine HCl Injection, USP is indicated for production of local or regional anesthesia by infiltration techniques such as percutaneous injection and intravenous regional anesthesia by peripheral nerve block techniques such as brachial plexus and intercostal and by central neural techniques such as lumbar and caudal epidural blocks, when the accepted procedures for these techniques as described in standard textbooks are observed.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2018 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Lidocaine Hydrochloride1% · injectable;injection | Lidocaine Hydrochloride | Rx |
| Oct 29, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Aug 3, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters